By Counterforce Health Team in Prolastin-C (alpha1-proteinase inhibitor) —

Renewing Prolastin-C Coverage with Cigna in Pennsylvania: Complete 2025 Guide to Authorization, Appeals, and Timing

Answer Box: Fastest Path to Prolastin-C Renewal

Cigna requires annual reauthorization for Prolastin-C in Pennsylvania. Start your renewal 60-90 days before expiration by gathering updated spirometry (within 6 months), recent clinical notes from your pulmonologist, and documentation of continued clinical benefit. Submit via your provider's Cigna portal or fax to 888-302-1028. If denied, you have 180 days for internal appeals and can use Pennsylvania's new external review program, which overturned 50% of denials in 2024.

First step today: Call your pulmonologist to schedule updated lung function tests and request they begin preparing your renewal packet.

Table of Contents

  1. Renewal Triggers: When to Start
  2. Evidence Update Requirements
  3. Your Renewal Packet Checklist
  4. Timeline and Decision Windows
  5. If Coverage Lapses
  6. 2025 Formulary Changes
  7. Appeals Process in Pennsylvania
  8. Common Denial Reasons & Solutions
  9. Cost Assistance Options
  10. FAQ

Renewal Triggers: When to Start

Cigna approves Prolastin-C for 1-year coverage periods, meaning you need annual reauthorization to continue therapy. Don't wait for an expiration notice—Accredo (Cigna's specialty pharmacy) may not always provide advance warning.

Start your renewal process when:

  • You're 60-90 days from authorization expiration
  • Your pulmonologist mentions upcoming lab work or spirometry
  • You receive any communication about coverage changes
  • It's been 10-11 months since your last approval
Tip: Mark your calendar for 3 months before expiration. This gives you time to gather documents, address any issues, and file appeals if needed.

Evidence Update Requirements

For Prolastin-C renewal, Cigna requires documentation that you're responding to therapy and still meet medical necessity criteria.

Required Clinical Documentation

Recent Spirometry (within 6 months):

  • FEV1 measurements showing stable or improved lung function
  • Comparison to baseline values from therapy initiation
  • Evidence that decline has slowed compared to pre-treatment rates

Updated Clinical Assessment:

  • Pulmonologist visit notes from the last 3 months
  • Documentation of continued AAT deficiency management
  • Assessment of treatment adherence and tolerance
  • Any changes in symptoms or exacerbation frequency

Laboratory Values:

  • Current AAT levels (target >11 μmol/L post-infusion)
  • Liver function tests if applicable
  • Confirmation of severe genotype (Pi*ZZ, null variants)

Demonstrating Clinical Benefit

Your renewal must show evidence of therapeutic response. According to Alpha-1 Foundation guidelines, this includes:

  • Slowed FEV1 decline: Annual spirometry showing therapy is preserving lung function
  • Reduced exacerbations: Fewer hospitalizations or urgent care visits
  • Maintained quality of life: Stable exercise tolerance and daily activities
  • Good adherence: Regular weekly infusions without significant gaps

Your Renewal Packet Checklist

Core Documents Required

1. Prior Authorization Form

  • Use current version from Cigna's provider portal
  • Complete all sections including dosing rationale (60 mg/kg weekly)
  • Include your specialist's NPI and practice information

2. Medical Necessity Letter Your pulmonologist should address:

  • Confirmed AAT deficiency with severe genotype
  • Baseline AAT levels <11 μmol/L (<80 mg/dL)
  • Evidence of emphysema or accelerated lung function decline
  • Prior therapy response and current clinical status
  • Rationale for continued weekly infusions

3. Supporting Clinical Evidence

  • Recent spirometry results (within 6 months)
  • Chest imaging if available (CT showing emphysema)
  • Treatment history and adherence records
  • Documentation of any alternative therapy failures

4. Prescription Details

  • Current dosing schedule (typically 60 mg/kg weekly)
  • Site of care (home infusion, clinic, hospital)
  • NDC codes and administration plan
  • Estimated treatment duration (ongoing)

Timeline and Decision Windows

Standard Review Process

Submit 60-90 days before expiration:

  • Allows time for information requests
  • Provides buffer for potential appeals
  • Ensures no treatment gaps

Cigna Decision Timeline:

  • Standard review: 15 business days from complete submission
  • Information requests: Additional 7-10 days if more documentation needed
  • Expedited review: 24-72 hours for urgent medical situations

Submission Methods

Preferred: Provider portal submission with electronic tracking Alternative: Fax to 888-302-1028 Phone: 866-759-1557 for verbal authorization support

Note: Always request confirmation of receipt and track your submission status through the provider portal.

If Coverage Lapses

If your authorization expires before renewal approval, immediate action is essential. Abrupt discontinuation of Prolastin-C can result in accelerated lung function decline.

Immediate Steps

  1. Contact Accredo: Call your specialty pharmacy to discuss temporary coverage options
  2. Physician outreach: Have your pulmonologist contact Cigna for expedited review
  3. Appeal preparation: Begin gathering documents for potential appeal
  4. Bridge therapy: Explore manufacturer assistance programs

Bridge Options to Discuss

While specific Cigna bridge programs aren't detailed in available sources, contact Accredo 30 days before expiration to discuss:

  • Emergency supply provisions
  • Temporary authorization extensions
  • Expedited review pathways for medical urgency

2025 Formulary Changes

Effective July 1, 2025, Cigna implemented new step therapy requirements for alpha1-proteinase inhibitors that affect coverage decisions.

Coverage at a Glance

Product Status Step Therapy Requirement PA Required
Prolastin-C Preferred None Yes, annual
Glassia Preferred None Yes, annual
Zemaira Non-preferred Must try/fail both preferred products Yes
Aralast NP Non-preferred Must try/fail both preferred products Yes

Good news for current patients: If you're already established on Prolastin-C, these changes support continued coverage as a preferred option.

What This Means for Renewals

  • Prolastin-C remains preferred under Cigna's updated policy
  • No additional step therapy required for current patients
  • Annual PA still required with same clinical criteria
  • Formulary position strengthened compared to alternatives

Appeals Process in Pennsylvania

Pennsylvania offers strong appeal rights, including a state-run external review program that overturned 50% of denials in 2024.

Internal Appeals with Cigna

First-Level Internal Appeal:

  • Deadline: 180 days from denial notice
  • Decision time: 30 days standard, 72 hours expedited
  • Submit to: Cigna appeals department via provider portal
  • Required: Complete denial letter, additional clinical evidence

Second-Level Internal Appeal:

  • Available if first-level appeal is denied
  • Same timeline and submission process
  • Include any new clinical information or specialist consultation

Pennsylvania External Review

After exhausting internal appeals, you can access Pennsylvania's Independent External Review Program.

Key Features:

  • Success rate: 50.1% of appeals overturned in 2024
  • Cost: Free to consumers
  • Deadline: 4 months from final internal denial
  • Submit: Online at pa.gov/reviewmyclaim
  • Timeline: 45 days standard, 72 hours expedited

Required Documentation:

  • Final Adverse Benefit Determination letter from Cigna
  • All medical records supporting medical necessity
  • Specialist letters addressing denial reasons
  • Clinical guidelines supporting Prolastin-C use
From our advocates: We've seen Pennsylvania's external review process work particularly well for rare disease treatments like Prolastin-C. The independent physician reviewers often have more specialized knowledge than initial utilization management staff, leading to coverage decisions that better reflect current medical evidence.

Common Denial Reasons & Solutions

Denial Reason Solution Strategy Key Documents
"Diagnosis not confirmed" Submit genetic testing, AAT levels Pi typing, serum AAT <11 μmol/L
"Not medically necessary" Provide specialist letter, guidelines ATS/ERS statements, FDA labeling
"Alternative therapy available" Document failures/contraindications Trial history, intolerance notes
"Dosing not appropriate" Justify weight-based calculation Current weight, 60 mg/kg rationale
"Insufficient documentation" Submit complete clinical picture Spirometry, imaging, treatment response

Medical Necessity Criteria

According to Cigna's policy IP0387, coverage requires:

  • Age: 18 years and older
  • Diagnosis: AAT deficiency with emphysema or panniculitis
  • Lab values: AAT serum level <80 mg/dL (or <11 μmol/L)
  • Genotype: Severe variants (Pi*ZZ, null, or Z variants)
  • Specialist care: Prescribed by pulmonologist or dermatologist
  • Non-smoker status: Current non-smoker or ex-smoker

Cost Assistance Options

With annual costs exceeding $80,000, financial assistance is crucial for many patients.

Manufacturer Support

  • Grifols Patient Assistance: Income-based support for uninsured/underinsured patients
  • Copay assistance: Available for commercial insurance (not Medicare)
  • Bridge programs: Temporary coverage during insurance transitions

Foundation Resources

  • Alpha-1 Foundation: Patient support and advocacy resources
  • NORD: Rare disease patient assistance programs
  • HealthWell Foundation: Copay assistance for chronic conditions

State Programs

  • Pennsylvania CHIP: Enhanced benefits for qualifying families
  • Medicaid: Coverage through Pennsylvania DHS programs
  • Insurance marketplace: Premium tax credits through Pennie

Counterforce Health specializes in turning insurance denials into successful appeals for complex treatments like Prolastin-C. Their platform helps patients and clinicians prepare evidence-backed appeals that align with payer-specific requirements, increasing approval rates for essential rare disease therapies.

FAQ

How long does Cigna prior authorization take in Pennsylvania? Standard review takes 15 business days from complete submission. Expedited review for urgent cases is decided within 24-72 hours.

What if Prolastin-C is non-formulary on my plan? Prolastin-C is preferred on most Cigna plans as of 2025. If non-formulary, request a formulary exception with medical necessity documentation.

Can I request an expedited appeal? Yes, if there's imminent health risk from therapy delay. Your physician must attest to medical urgency in the appeal submission.

Does step therapy apply if I was stable on Prolastin-C before moving to Pennsylvania? Generally no. Established therapy with documented clinical benefit typically qualifies for continuation without step therapy requirements.

What happens if my appeal is denied? You can proceed to Pennsylvania's external review program, which overturned 50% of denials in 2024. This independent review is free and binding on insurers.

How do I track my authorization status? Use Cigna's provider portal for real-time status updates, or call member services at the number on your insurance card.

Can my doctor do a peer-to-peer review? Yes, your pulmonologist can request a peer-to-peer discussion with Cigna's medical director to discuss clinical rationale directly.

What if I need treatment while my appeal is pending? Contact Accredo about emergency supplies and explore manufacturer patient assistance programs for temporary coverage.

Sources & Further Reading

For complex cases requiring specialized appeal support, Counterforce Health provides expert assistance in preparing evidence-backed appeals that address payer-specific requirements and increase approval rates for essential rare disease treatments.

This information is for educational purposes only and does not constitute medical advice. Always consult with your healthcare provider and insurance plan for specific coverage decisions. For assistance with Pennsylvania insurance appeals, contact the Pennsylvania Insurance Department at 1-877-881-6388.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.